Phase 2 N=162 Dose Finding Study to Treat High Phosphate Levels in the Blood.
Hyperphosphatemia
Primary: Change in Serum Phosphate Levels — -.47; -1.18; -1.7; -1.98 mg/dL — p=0.012
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=566 Aclidinium/Formoterol Fixed Combination Dose Finding Study
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr — 0.170; 0.219; 0.230; 0.075 Liters — p=<0.0001
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 1 N=59 Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
Neoplasms
Primary: Percentage of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib — 0.0; 0.0; 16.7; 23.5…
Phase 1 N=32 Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Neoplasms
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 participants
Phase 1 N=46 A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors
Neoplasm
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 2 N=135 A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
Hypertension
Primary: Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28 — 1.38; -1.42; -3.28; -5.59…
Phase 1 N=29 Dose Finding Study of BI 836880 in Patients With Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 720 Milligram
Phase 2 N=834 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Migraine
Primary: Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose — 8.9; 5.6; 14.8; 21.4 percentage of participants
Phase 2 N=12 Dose Finding Safety Study of VAL201 in Cancer Patients
Stage III Prostate Carcinoma · Stage IV Prostate Carcinoma
Primary: Dose-Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=130 Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions — 1.03; 1.39; 0.77; 0.76 lesions — p=0.1673
Phase 2 N=123 Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Gastrointestinal Endoscopy · Gastrointestinal Polypectomy
Primary: Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 2 Minutes From Beginning of Maintenance Period — 0; 0; 0; 1 Participants
Phase 2 N=141 Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 12 — -0.35; -0.60; -0.84; -0.73 percentage of A1C — p=0.07
Phase 2 N=342 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
CINV
Primary: Number of Participants With Delayed Phase Complete Response(CR) — 37; 13; 27; 21 Participants — p=0.004
Phase 2 N=174 A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score — -10.1; -4.4 Scores on a scale
Phase 1 N=49 A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=198 A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
Anxiety Generalized
Primary: Dose Response — -14.23; -15.35; -16.05; -19.22 units on a scale
Phase 2 N=232 Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: Duration of Moderate Neurtopenia Post First Chemotherapy Administration — 0.6; 0.6; 0.4; 0.3 days
Phase 2 N=97 Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 19; 20; 20 Participants — p=0.6604
Phase 2 N=394 A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Absolute Change in HbA1c — 7.872; 7.939; 8.006; 7.998 Percentage
Phase 2 N=420 A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
Migraine
Primary: Pain Relief at 2 Hours — 52; 5; 9; 8 Participants — p=0.015
Phase 2 N=189 Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Testosterone <=0.5 Nanograms/Milliliter From Day 28 to Day 364 — 17; 21; 26; 27 participants
Phase 2 N=153 Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
SARS-CoV-2 Virus Infection
Primary: Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series — 35; 31; 36; 32 events
Phase 1 N=69 Monotherapy Dose Finding With BI 847325 in Solid Tumours
Neoplasms
Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants
Phase 2 N=101 Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children
Procedural Anxiety
Primary: Number of Children Who Achieved PSSS Score 2, 3, or 4 for 95% or Greater of the Scored Procedure — 9; 12; 20; 19 Participants
Phase 2 N=67 Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Score — 0.0; -3.7; -3.4; -3.9 score on a scale…
Phase 2 N=122 Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. — 17; 10; 7; 4…
Phase 1 N=40 A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
Schizophrenia
Primary: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation — 4; 4; 2; 4 count of participants
Phase 2 N=25 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Autosomal Dominant Polycystic Kidney Disease
Primary: Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7. — 140; 175; 350…
Phase 2 N=60 Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Anemia · Dialysis Dependent Chronic Kidney Disease
Primary: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period — -0.28; 0.08; 0.41; -1.48 grams per deciliter (g/dL) — p=0.0004